Key result
Novel SailValve yields 100% immediate patency and sustained midterm function in a porcine model.
Why the study?
The potential of a new self-expanding deep venous valve concept to reduce thrombogenicity and improve valve function needed evaluation in a preclinical model.
Does the SailValve self-expanding deep venous valve system maintain patency and function in a porcine model?
Does the SailValve self-expanding deep venous valve system maintain patency and function in a porcine model?
The SailValve self-expanding deep venous valve system demonstrated technical feasibility, short-term patency, and partial functional success in a porcine model.
Answers are grounded in this paper and cite their sources.
Supports feasibility in porcine model; hypothesis-generating and should not inform clinical practice.
PURPOSE: To evaluate the SailValve, a new self-expanding deep venous valve concept based on a single polytetrafluoroethylene cusp floating up and down in the bloodstream like a sail, acting as a flow regulator and allowing minimal reflux to reduce thrombogenicity. METHODS: Both iliac veins of 5 pigs were implanted with SailValve devices; the first animal was an acute pilot experiment to show the feasibility of accurately positioning the SailValve via a femoral access. The other 4 animals were followed for 2 weeks (n=2) or 4 weeks (n=2) under a chronic implantation protocol. Patency and valve function were evaluated directly in all animals using ascending and descending phlebography after device placement and at termination in the chronic implant animals. For reasons of clinical relevance, a regimen of clopidogrel and calcium carbasalate was administered. Histological analysis was performed according to a predefined protocol by an independent pathologist. RESULTS: Deployment was technically feasible in all 10 iliac veins, and all were patent directly after placement. No perioperative or postoperative complications occurred. Ascending phlebograms in the follow-up animals confirmed the patency of all valves after 2 or 4 weeks. Descending phlebograms showed full function in 5 of 8 valves. Limited reflux was seen in 1 valve (4-week group), and the function in the remaining 2 valves (2-week group) was insufficient because of malpositioning. No macroscopic thrombosis was noted on histology. Histology in the follow-up groups revealed a progressive inflammatory reaction to the valves. CONCLUSION: This animal study shows the potential of the SailValve concept with sufficient valve function after adequate positioning and no (thrombogenic) occlusions after short-term follow-up. Future research is essential to optimize valve material and long-term patency.
No takes yet. Share an insight, caveat, or question.
Boersma et al. (2017) studied Deep venous valve evaluation (n=5). SailValve Self-Expanding Deep Venous Valve System was evaluated on Patency and valve function. Implantation of the SailValve in a porcine model achieved 100% patency directly after placement and full function in 5 of 8 valves at 2 to 4 weeks follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: